Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe
- 1 November 2004
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 18 (17), 2337-2339
- https://doi.org/10.1097/00002030-200411190-00019
Abstract
Highly active antiretroviral therapy (HAART) may be associated with adverse pregnancy outcomes. Among 4372 live births in the European Collaborative Study, the prematurity rate increased to 24.9% in 2000-2004. Antenatal HAART use initiated pre-pregnancy was strongly associated with prematurity (AOR 2.05, 95% CI 1.43, 2.95), particularly severe prematurity. The implication of increased prematurity is evidenced in high neonatal mortality in these groups (0.66% for infants at 34-36 weeks and 7.37% at < 34 weeks' gestation).Keywords
This publication has 3 references indexed in Scilit:
- Exposure to Antiretroviral Therapy in Utero or Early Life: the Health of Uninfected Children Born to HIV-Infected WomenJAIDS Journal of Acquired Immune Deficiency Syndromes, 2003
- Antiretroviral Therapy during Pregnancy and the Risk of an Adverse OutcomeNew England Journal of Medicine, 2002
- Combination antiretroviral therapy and duration of pregnancyAIDS, 2000